Analyst Viewpoint
Rise in prevalence of chronic diseases is propelling the drug and gene delivery systems market size. Increase in work-related stress and geriatric population has led to rise in cases of cardiovascular diseases, diabetes, and asthma, globally. Drug and gene delivery systems improve efficiency and safety standards for the treatment of chronic diseases, especially for auto-immune disorders and several cancers including brain, lung, pancreatic, and liver.
Prominent players operating in the drug and gene delivery systems sector are investing in the R&D of advanced delivery systems to combat long term sickness. Advancements in fields of genomics, biotechnology, and nanotechnology are boosting the drug and gene delivery systems market progress.
Gene delivery systems are used to introduce foreign genetic materials, such as DNA and RNA, into a host cell. Gene delivery is critical to gene therapy. It can manipulate gene materials by either silencing a gene component or integrating with it. The approach is employed for the treatment of several diseases inherited disorders, certain types of cancer, and viral infections.
Drug delivery systems improve efficacy of treatment by carrying drugs into or throughout the body. They are applied in regenerative medicine to introduce therapeutic proteins against degeneration if controlled access is achievable. Advancements in the field of genomics and drug delivery coupled with rise in cases of cardiovascular diseases, asthma, and diabetes are fueling the drug and gene delivery systems market value.
Rapid unplanned urbanization, unhealthy habits, work stress, and ageing population are some of the major factors contributing to the surge in prevalence of chronic diseases worldwide. As per the World Health Organization, diabetes, cardiovascular diseases, cancer, and respiratory illnesses are expected to account for a staggering 86% of the 90 million deaths per year by 2050. Hence, increase in prevalence of chronic diseases is propelling the drug and gene delivery systems market development.
Gene therapy that relies on drug delivery platforms is revolutionary for chronic disease treatment as it allows healthcare providers to treat an illness at its microscopic source in a safe and accessible way. Drug and gene delivery systems improve efficiency and safety standards for chronic disease treatment, especially for auto-immune disorders and several cancers including brain, lung, pancreatic, and liver.
Advancements in nanotechnology and biotechnology enable the development and manufacture of novel drugs that apply more personalized and precise drug and gene delivery systems. Ongoing research in the field of genomics and investment by pharmaceutical companies to improve their drug delivery systems is expected to spur the drug and gene delivery systems market growth in the near future.
As per reports by Statista, biotechnology firms in Germany spent over US$ 4.6 Bn on research and development. Pharmaceutical companies spend around 20% of their revenue on the development of new products and the numbers are set to only go upwards during the forecast period.
According to the latest drug and gene delivery systems market analysis, North America held largest share in 2022. Surge in cases of chronic diseases and increase in healthcare expenditure are augmenting the market dynamics of the region. As per the Centers for Disease Control and Prevention (CDC), more than half of the adults in the U.S. suffer from at least one chronic disease. Moreover, the geriatric population in the country is set to make up 40% of the population by 2040, enhancing the burden on healthcare system.
According to the latest drug and gene delivery systems market forecast, the industry in Asia Pacific is projected to grow at a steady pace from 2023 to 2031. Rise in prevalence of HIV and cancer in developing economies is propelling the market statistics in the region.
According to the recent drug and gene delivery systems market trends, prominent manufacturers are investing heavily in the development of gene delivery platforms and drug delivery technologies to combat chronic diseases and offer advanced precise treatment options.
Novartis AG, Amgen Inc., Oxford BioMedica plc., SIBIONO, Shanghai Sunway Biotech Co., Ltd., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Bayer AG, Johnson & Johnson Services, Inc., Becton, Dickinson and Company, AstraZeneca plc., Baxter International, Inc., Boston Scientific Corporation, and GenVivo, Inc. are key manufacturers of drug and gene delivery systems.
The drug and gene delivery systems market report covers these companies in terms of parameters such as company overview, business strategies, product portfolio, financial overview, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 3.4 Bn |
| Market Forecast Value in 2031 | US$ 7.8 Bn |
| Growth Rate (CAGR) | 10.0% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape | Prominent Players – Competition Dashboard and Revenue Share Analysis, 2022 Company Profiles (Details – Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview) |
| Format | Electronic (PDF) + Excel |
| Regions Covered |
|
| Countries Covered |
|
| Market Segmentation |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 3.4 Bn in 2022
It is projected to advance at a CAGR of 10.0% from 2023 to 2031
Rise in prevalence of chronic diseases and advancements in biotechnology
The drug delivery systems segment held the largest share in 2022
North America was the leading region in 2022
Novartis AG, Amgen Inc., Oxford BioMedica plc., SIBIONO, Shanghai Sunway Biotech Co., Ltd., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Bayer AG, Johnson & Johnson Services, Inc., Becton, Dickinson and Company, AstraZeneca plc., Baxter International, Inc., Boston Scientific Corporation, and GenVivo, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Drug and Gene Delivery Systems Market
4. Market Overview
4.1. Introduction
4.1.1. Delivery System Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Drug and Gene Delivery Systems Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Delivery System/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Delivery System
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Delivery System, 2017–2031
6.3.1. Drug Delivery Systems
6.3.1.1. Intrauterine Implants
6.3.1.2. Prodrug Implants
6.3.1.3. Polymeric Drug Delivery
6.3.1.4. Targeted Drug Delivery
6.3.2. Gene Delivery Systems
6.3.2.1. Viral Gene Delivery
6.3.2.1.1. Adenovirus Vector
6.3.2.1.2. Lentivirus Vector
6.3.2.1.3. Retrovirus Vector
6.3.2.1.4. Adeno-associated Virus Vector
6.3.2.1.5. Sendai Virus Vector
6.3.2.1.6. Herpes Simplex Virus Vector
6.3.2.1.7. Others
6.3.2.2. Non-viral Gene Delivery
6.3.2.2.1. Natural Organic Compounds
6.3.2.2.2. Physical Methods
6.3.2.2.3. Chemical Methods
6.3.2.3. Combined Hybrid System
6.4. Market Attractiveness Analysis, by Delivery System
7. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Injectable
7.3.3. Inhalation
7.3.4. Transdermal
7.3.5. Ocular
7.3.6. Nasal
7.3.7. Topical
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017–2031
8.3.1. Infectious Diseases
8.3.2. Oncology
8.3.3. Ophthalmology
8.3.4. Urology
8.3.5. Diabetes
8.3.6. CNS
8.3.7. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Drug and Gene Delivery Systems Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Delivery System, 2017–2031
10.3.1. Drug Delivery Systems
10.3.1.1. Intrauterine Implants
10.3.1.2. Prodrug Implants
10.3.1.3. Polymeric Drug Delivery
10.3.1.4. Targeted Drug Delivery
10.3.2. Gene Delivery Systems
10.3.2.1. Viral Gene Delivery
10.3.2.1.1. Adenovirus Vector
10.3.2.1.2. Lentivirus Vector
10.3.2.1.3. Retrovirus Vector
10.3.2.1.4. Adeno-associated Virus Vector
10.3.2.1.5. Sendai Virus Vector
10.3.2.1.6. Herpes Simplex Virus Vector
10.3.2.1.7. Others
10.3.2.2. Non-viral Gene Delivery
10.3.2.2.1. Natural Organic Compounds
10.3.2.2.2. Physical Methods
10.3.2.2.3. Chemical Methods
10.3.2.3. Combined Hybrid System
10.4. Market Value Forecast, by Route of Administration, 2017–2031
10.4.1. Oral
10.4.2. Injectable
10.4.3. Inhalation
10.4.4. Transdermal
10.4.5. Ocular
10.4.6. Nasal
10.4.7. Topical
10.5. Market Value Forecast, by Application, 2017–2031
10.5.1. Infectious Diseases
10.5.2. Oncology
10.5.3. Ophthalmology
10.5.4. Urology
10.5.5. Diabetes
10.5.6. CNS
10.5.7. Others
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Delivery System
10.7.2. By Route of Administration
10.7.3. By Application
10.7.4. By Country
11. Europe Drug and Gene Delivery Systems Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Delivery System, 2017–2031
11.3.1. Drug Delivery Systems
11.3.1.1. Intrauterine Implants
11.3.1.2. Prodrug Implants
11.3.1.3. Polymeric Drug Delivery
11.3.1.4. Targeted Drug Delivery
11.3.2. Gene Delivery Systems
11.3.2.1. Viral Gene Delivery
11.3.2.1.1. Adenovirus Vector
11.3.2.1.2. Lentivirus Vector
11.3.2.1.3. Retrovirus Vector
11.3.2.1.4. Adeno-associated Virus Vector
11.3.2.1.5. Sendai Virus Vector
11.3.2.1.6. Herpes Simplex Virus Vector
11.3.2.1.7. Others
11.3.2.2. Non-viral Gene Delivery
11.3.2.2.1. Natural Organic Compounds
11.3.2.2.2. Physical Methods
11.3.2.2.3. Chemical Methods
11.3.2.3. Combined Hybrid System
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Oral
11.4.2. Injectable
11.4.3. Inhalation
11.4.4. Transdermal
11.4.5. Ocular
11.4.6. Nasal
11.4.7. Topical
11.5. Market Value Forecast, by Application, 2017–2031
11.5.1. Infectious Diseases
11.5.2. Oncology
11.5.3. Ophthalmology
11.5.4. Urology
11.5.5. Diabetes
11.5.6. CNS
11.5.7. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Delivery System
11.7.2. By Route of Administration
11.7.3. By Application
11.7.4. By Country/Sub-region
12. Asia Pacific Drug and Gene Delivery Systems Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Delivery System, 2017–2031
12.3.1. Drug Delivery Systems
12.3.1.1. Intrauterine Implants
12.3.1.2. Prodrug Implants
12.3.1.3. Polymeric Drug Delivery
12.3.1.4. Targeted Drug Delivery
12.3.2. Gene Delivery Systems
12.3.2.1. Viral Gene Delivery
12.3.2.1.1. Adenovirus Vector
12.3.2.1.2. Lentivirus Vector
12.3.2.1.3. Retrovirus Vector
12.3.2.1.4. Adeno-associated Virus Vector
12.3.2.1.5. Sendai Virus Vector
12.3.2.1.6. Herpes Simplex Virus Vector
12.3.2.1.7. Others
12.3.2.2. Non-viral Gene Delivery
12.3.2.2.1. Natural Organic Compounds
12.3.2.2.2. Physical Methods
12.3.2.2.3. Chemical Methods
12.3.2.3. Combined Hybrid System
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Injectable
12.4.3. Inhalation
12.4.4. Transdermal
12.4.5. Ocular
12.4.6. Nasal
12.4.7. Topical
12.5. Market Value Forecast, by Application, 2017–2031
12.5.1. Infectious Diseases
12.5.2. Oncology
12.5.3. Ophthalmology
12.5.4. Urology
12.5.5. Diabetes
12.5.6. CNS
12.5.7. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Delivery System
12.7.2. By Route of Administration
12.7.3. By Application
12.7.4. By Country/Sub-region
13. Latin America Drug and Gene Delivery Systems Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Delivery System, 2017–2031
13.3.1. Drug Delivery Systems
13.3.1.1. Intrauterine Implants
13.3.1.2. Prodrug Implants
13.3.1.3. Polymeric Drug Delivery
13.3.1.4. Targeted Drug Delivery
13.3.2. Gene Delivery Systems
13.3.2.1. Viral Gene Delivery
13.3.2.1.1. Adenovirus Vector
13.3.2.1.2. Lentivirus Vector
13.3.2.1.3. Retrovirus Vector
13.3.2.1.4. Adeno-associated Virus Vector
13.3.2.1.5. Sendai Virus Vector
13.3.2.1.6. Herpes Simplex Virus Vector
13.3.2.1.7. Others
13.3.2.2. Non-viral Gene Delivery
13.3.2.2.1. Natural Organic Compounds
13.3.2.2.2. Physical Methods
13.3.2.2.3. Chemical Methods
13.3.2.3. Combined Hybrid System
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Injectable
13.4.3. Inhalation
13.4.4. Transdermal
13.4.5. Ocular
13.4.6. Nasal
13.4.7. Topical
13.5. Market Value Forecast, by Application, 2017–2031
13.5.1. Infectious Diseases
13.5.2. Oncology
13.5.3. Ophthalmology
13.5.4. Urology
13.5.5. Diabetes
13.5.6. CNS
13.5.7. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Delivery System
13.7.2. By Route of Administration
13.7.3. By Application
13.7.4. By Country/Sub-region
14. Middle East & Africa Drug and Gene Delivery Systems Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Delivery System, 2017–2031
14.3.1. Drug Delivery Systems
14.3.1.1. Intrauterine Implants
14.3.1.2. Prodrug Implants
14.3.1.3. Polymeric Drug Delivery
14.3.1.4. Targeted Drug Delivery
14.3.2. Gene Delivery Systems
14.3.2.1. Viral Gene Delivery
14.3.2.1.1. Adenovirus Vector
14.3.2.1.2. Lentivirus Vector
14.3.2.1.3. Retrovirus Vector
14.3.2.1.4. Adeno-associated Virus Vector
14.3.2.1.5. Sendai Virus Vector
14.3.2.1.6. Herpes Simplex Virus Vector
14.3.2.1.7. Others
14.3.2.2. Non-viral Gene Delivery
14.3.2.2.1. Natural Organic Compounds
14.3.2.2.2. Physical Methods
14.3.2.2.3. Chemical Methods
14.3.2.3. Combined Hybrid System
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Injectable
14.4.3. Inhalation
14.4.4. Transdermal
14.4.5. Ocular
14.4.6. Nasal
14.4.7. Topical
14.5. Market Value Forecast, by Application, 2017–2031
14.5.1. Infectious Diseases
14.5.2. Oncology
14.5.3. Ophthalmology
14.5.4. Urology
14.5.5. Diabetes
14.5.6. CNS
14.5.7. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Delivery System
14.7.2. By Route of Administration
14.7.3. By Application
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Novartis AG
15.3.1.1. Company Overview
15.3.1.2. Delivery System Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Amgen Inc.
15.3.2.1. Company Overview
15.3.2.2. Delivery System Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Oxford BioMedica plc.
15.3.3.1. Company Overview
15.3.3.2. Delivery System Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. SIBIONO
15.3.4.1. Company Overview
15.3.4.2. Delivery System Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Shanghai Sunway Biotech Co., Ltd.
15.3.5.1. Company Overview
15.3.5.2. Delivery System Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. F. Hoffmann-La Roche Ltd.
15.3.6.1. Company Overview
15.3.6.2. Delivery System Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Pfizer, Inc.
15.3.7.1. Company Overview
15.3.7.2. Delivery System Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Bayer AG
15.3.8.1. Company Overview
15.3.8.2. Delivery System Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Johnson & Johnson Services, Inc.
15.3.9.1. Company Overview
15.3.9.2. Delivery System Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Becton, Dickinson and Company
15.3.10.1. Company Overview
15.3.10.2. Delivery System Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. AstraZeneca plc
15.3.11.1. Company Overview
15.3.11.2. Delivery System Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Baxter International, Inc.
15.3.12.1. Company Overview
15.3.12.2. Delivery System Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Boston Scientific Corporation
15.3.13.1. Company Overview
15.3.13.2. Delivery System Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. GenVivo, Inc.
15.3.14.1. Company Overview
15.3.14.2. Delivery System Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview
List of Tables
Table 01: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031
Table 02: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 03: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 04: Global Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031
Table 07: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 08: North America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 09: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031
Table 11: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 12: Europe Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 13: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031
Table 15: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 16: Asia Pacific Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 17: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031
Table 19: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 20: Latin America Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 21: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031
Table 23: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 24: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast, by Application, 2017–2031
List of Figures
Figure 01: Global Drug and Gene Delivery Systems Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Drug and Gene Delivery Systems Market Revenue (US$ Mn), by Delivery System, 2022
Figure 03: Global Drug and Gene Delivery Systems Market Value Share, by Delivery System, 2022
Figure 04: Global Drug and Gene Delivery Systems Market Revenue (US$ Mn), by Route of Administration, 2022
Figure 05: Global Drug and Gene Delivery Systems Market Value Share, by Route of Administration, 2022
Figure 06: Global Drug and Gene Delivery Systems Market Revenue (US$ Mn), by Application, 2022
Figure 07: Global Drug and Gene Delivery Systems Market Value Share, by Application, 2022
Figure 08: Global Drug and Gene Delivery Systems Market Value Share, by Region, 2022
Figure 09: Global Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast, 2023–2031
Figure 10: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
Figure 11: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023-2031
Figure 12: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 13: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 14: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
Figure 15: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2022-2031
Figure 16: Global Drug and Gene Delivery Systems Market Value Share Analysis, by Region, 2022 and 2031
Figure 17: Global Drug and Gene Delivery Systems Market Attractiveness Analysis, by Region, 2022-2031
Figure 18: North America Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Country, 2022 and 2031
Figure 21: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
Figure 22: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 23: North America Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
Figure 24: North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023–2031
Figure 25: North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 26:North America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023–2031
Figure 27: Europe Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
Figure 31: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 32: Europe Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
Figure 33: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023–2031
Figure 34: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 35: Europe Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023–2031
Figure 36: Asia Pacific Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
Figure 40: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 41: Asia Pacific Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
Figure 42: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023–2031
Figure 43: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 44: Asia Pacific Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023–2031
Figure 45: Latin America Drug and Gene Delivery Systems Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
Figure 49: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 50: Latin America Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
Figure 51: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023–2031
Figure 52: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 53: Latin America Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023–2031
Figure 54: Middle East & Africa Drug and Gene Delivery Systems Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Delivery System, 2022 and 2031
Figure 58: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 59: Middle East & Africa Drug and Gene Delivery Systems Market Value Share Analysis, by Application, 2022 and 2031
Figure 60: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Delivery System, 2023–2031
Figure 61: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Route of Administration, 2023–2031
Figure 62: Middle East & Africa Drug and Gene Delivery Systems Market Attractiveness Analysis, by Application, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Drug and Gene Delivery Systems Market
*86 figures and 60 tables includes